These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 2150753)

  • 1. trans-Dominant suppressor mutations of the H-ras oncogene.
    Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
    Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversion and rereversion in ras-transformed cells.
    Marshall CJ
    Immunol Ser; 1990; 51():89-106. PubMed ID: 2128917
    [No Abstract]   [Full Text] [Related]  

  • 3. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversion of middle T antigen-transformed Rat-2 cells by Krev-1: implications for the role of p21c-ras in polyomavirus-mediated transformation.
    Jelinek MA; Hassell JA
    Oncogene; 1992 Sep; 7(9):1687-98. PubMed ID: 1380149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes.
    Stacey DW; Roudebush M; Day R; Mosser SD; Gibbs JB; Feig LA
    Oncogene; 1991 Dec; 6(12):2297-304. PubMed ID: 1766676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interplay between ras oncogenes and tumor suppressor genes in experimental carcinogenesis.
    Balmain A; Brown K; Bremner R
    Immunol Ser; 1990; 51():75-88. PubMed ID: 2128916
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
    Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
    Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
    Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
    Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
    Velasco JA; Avila MA; Notario V
    Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
    Yokoyama T
    Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant.
    Ogiso Y; Yokoyama T; Watari H; Shih TY; Kuzumaki N
    Exp Cell Res; 1993 Oct; 208(2):415-21. PubMed ID: 7690710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of azatyrosine-induced revertants from ras-transformed human mammary epithelial cells.
    Kyprianou N; Taylor-Papadimitriou J
    Oncogene; 1992 Jan; 7(1):57-63. PubMed ID: 1741165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformation suppressor genes.
    Noda M; Kitayama H; Kanazawa S; Murata S; Matsuzaki T; Ikawa Y
    Princess Takamatsu Symp; 1989; 20():233-9. PubMed ID: 2518686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
    Saez R; Chan AM; Miki T; Aaronson SA
    Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene.
    Takahashi C; Akiyama N; Matsuzaki T; Takai S; Kitayama H; Noda M
    Oncogene; 1996 May; 12(10):2137-46. PubMed ID: 8668339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
    Kuo ML; Chou YW; Chau YP; Huang TS
    Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role of Rho in cell transformation by oncogenic Ras.
    Prendergast GC; Khosravi-Far R; Solski PA; Kurzawa H; Lebowitz PF; Der CJ
    Oncogene; 1995 Jun; 10(12):2289-96. PubMed ID: 7784077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.
    Li W; Michieli P; Alimandi M; Lorenzi MV; Wu Y; Wang LH; Heidaran MA; Pierce JH
    Oncogene; 1996 Aug; 13(4):731-7. PubMed ID: 8761294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversion of Ras transformed cells by Ets transdominant mutants.
    Wasylyk C; Maira SM; Sobieszczuk P; Wasylyk B
    Oncogene; 1994 Dec; 9(12):3665-73. PubMed ID: 7970725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.